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Nonalcoholic fatty liver disease (NAFLD) is the most
common chronic liver disorder in industrialized coun-
tries. Liver samples from morbidly obese patients (n =
45) with all stages of NAFLD and controls (n = 18) were
analyzed by array-based DNA methylation and mRNA
expression profiling. NAFLD-specific expression and
methylation differences were seen for nine genes cod-
ing for key enzymes in intermediatemetabolism (inclu-
ding PC, ACLY, and PLCG1) and insulin/insulin-like
signaling (including IGF1, IGFBP2, andPRKCE) and re-
plicated by bisulfite pyrosequening (independent n =
39). Transcription factor binding sites at NAFLD-spe-
cific CpG sites were >1,000-fold enriched for ZNF274,
PGC1A, and SREBP2. Intraindividual comparison of
liverbiopsiesbeforeandafterbariatric surgery showed
NAFLD-associatedmethylation changes tobepartially
reversible. Postbariatric and NAFLD-specific methy-
lation signatures were clearly distinct both in gene
ontologyand transcription factorbindingsiteanalyses,
with >400-fold enrichment of NRF1, HSF1, and ESRRA
sites. Our findings provide an example of treatment-
induced epigenetic organ remodeling in humans.
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) describes a spectrum
of liver disorders that occurs in the context of obesity and type 2
diabetes mellitus (Chalasani et al., 2012). While pure steatosis is296 Cell Metabolism 18, 296–302, August 6, 2013 ª2013 Elsevier Inca largely benign condition, it can be complicated by nonalcoholic
steatohepatitis (NASH), which can progress to cirrhosis and liver
failure. The pathogenesis of NAFLD ismultifactorial and triggered
by environmental factors such as hypercaloric nutrition and lack
of physical activity in the context of genetic predisposition (Chala-
sani et al., 2010; Romeo et al., 2008). Bariatric surgery is themost
radical therapy for the metabolic syndrome and NASH, leading
typically to massive weight loss, improvement of liver histology
(Dixon et al., 2004), and all-cause mortality (Lundell, 2012).
DNA methylation represents a level of epigenetic regulation
that is closely linked to transcription factor (TF) binding and chro-
matin accessibility. While DNA methylation been studied inten-
sively in cancer, including hepatocellular carcinoma (Ammerpohl
et al., 2012), its pathogenetic role in benign disorders is only
recently being recognized. DNA methylation signatures are not
static but can be remodeled by TFs (Stadler et al., 2011) and
by environmental stimuli (Barre`s et al., 2012). The relevance of
differential DNA methylation in NAFLD has been demonstrated
for PPARGC1A, which showed a tight interaction to the insulin
resistance phenotype (Sookoian et al., 2010) and by differential
susceptibility of mice to hepatic steatosis (Pogribny et al.,
2009) based on their epigenetic profiles.
Here we present a systematic analysis of DNA methylation in
NAFLD and its dynamic remodeling after the massive weight
loss induced by bariatric surgery.RESULTS
Differences in DNA Methylation between Liver
Phenotypes
Snap-frozen liver biopsies were obtained from 63 patients and
classified histologically using the nonalcoholic fatty liver activity.
Table 1. Sample Overview for the Discovery and Replication Samples













Discovery N methylation 18 18 12 15 n/a 23 n/a
Age 51 [44–72] 44 [41–50] 46 [37–49] 47 [40–50] 47 [38–51] n/a
BMI 24 [21–26] 45 [42–49] 50 [47–55] 49 [44–56] 48 [45–54] 34 [30–40] 14 [12–16]
Weight (kg) 67 [58–64] 135 [122–150] 147 [121–166] 146 [133–168] 146 [134–160] 106 [87–116] 40 [49– 34]
Sex (% male) 50 0 42 27 17 17 n/a
Diabetes (%) 11 17 25 20 26 17 9
Fat (area in %) 0 [0–1] 3 [0–4] 43 [20–70] 75 [70–85] 30 [12–70] 0 [3–25] 16 [5–40]
Inflammation (0–3) 0 [0–0] 0 [0–0] 0 [0–0] 2 [1–2] 0 [0–1] 0 [0–0] 0 [1–0]
Fibrosis (0–4) 0 [0–0] 0 [0–0] 0 [0–1] 1 [0–1] 0 [0–1] 0 [0–0] 0 [0–1]
NAS (0–8) 0 [0–0] 0 [0–0] 2 [1–3] 5 [5–6] 2 [1–5] 0 [0–1.5] 2 [1–3]
N mRNA (N overlap
with methylation set)
12 (11) 16 (16) 9 (8) 17 (15) n/a 16 (16) n/a
Replication N 10 9 10 10
Age 74 [66–77] 37 [34–43] 42 [31–59] 40 [35–47]
BMI 25 [23–26] 48 [46–51] 47 [40–57] 58 [57–59]
Weight (kg) 67 [62–72] 137 [128–144] 140 [117–162] 165 [159–186]
Sex (% male) 20 11 10 20
Diabetes (%) 20 0 40 20
Fat (area in %) 0 [0–0] 3 [2–5] 65 [31–78] 80 [70–82]
Inflammation (0–3) 0 [0–0] 0 [0–0] 0 [0–0] 1 [1–2]
Fibrosis (0–4) 0 [0–0] 0 [0–0] 0 [0–0] 1 [1–1]
NAS (0–8) 0 [0–0] 0 [0–1] 2 [1–3] 5 [5–6]
The median and the interquartile range are provided for all numeric parameters. All prebariatric patients and no postbariatric patients are part of the
liver phenotype samples. For the postbariatric samples, the change in the parameters is provided in the separate column. RNA for expression analysis
was available for 70 liver samples, of which 66 were obtained from the same individuals who were used in the methylation experiment (in brackets).
‘‘Bariatric samples’’ refers strictly to patients for whom paired biopsies were available. The majority of the ‘‘liver phenotype samples’’ (H/S/N, 82%,
87%, and 90%) were obtained during bariatric surgery as well.
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DNA Methylation in NASH and Liver Remodelingscore (Kleiner et al., 2005) and clinically into normal controls
(n = 18), healthy obese (n = 18), steatosis (n = 12), and NASH
(n = 15). These biopsies are referred to as ‘‘liver phenotype
samples.’’ For 23 of these individuals (H/S/N: 7/10/6), follow-
up liver biopsies 5–9 months after bariatric surgery were avail-
able. These postsurgery samples are referred to as ‘‘bariatric
samples,’’ bringing the total of analyzed liver biopsies to 86.
The bariatric patients showed the expected improvement of
liver histology (Dixon et al., 2004; Mathurin et al., 2006) (Table 1).
All samples were assayed for CpG methylation at over 450,000
sites using an array-based approach. Array-based mRNA
expression data were available for 70 liver samples, of which
66 were obtained from the same individuals as used in the
methylation experiment (Table 1).
First, all sites deviating at least in one of the four phenotypic
groups from the overall medianmethylation were identified using
an omnibus (Kruskal-Wallis) test at a nominal significance of
p < 0.0001. For the 273 CpG sites meeting this significance
criterion, the medians of DNA methylation for each phenotype
were sorted from lowest to highest. Under the null hypothesis,
each of the 24 possible phenotype permutations would be
equally abundant. However, particular ordered phenotype
permutations were found to be strongly enriched (p < 1014,Celsee Table S1A online), namely those compatible with a pheno-
typic progression from normal controls (C) to healthy obese
(H), to steatosis (S), to NASH (N).
Second, we aimed to identify CpGs differentially methylated
between phenotypic groups. In a global cluster and principal
components analysis (PCA) at a false discovery threshold
level of q = 0.05, 467 CpG loci were identified to be differentially
methylated between the four phenotypic groups (online supple-
ments can be found at http://gengastro.1med.uni-kiel.de/suppl/
methyl_liver/). For ease of visualization, this analysis was
repeated using q = 0.004, yielding 74 differentially methylated
sites (Figure 1A). Both the heatmap and the PCA of these differ-
entially methylated sites show normal liver samples and NASH
as the extreme groups with healthy obese and steatosis samples
located in the intermediate.
Expression Differences of Transcripts in the Liver
Phenotype Comparison
Messenger RNA expression for the 294 genes annotated to the
467 CpGs differentially methylated between the four phenotypic
groups was analyzed: 272 of these genes were present on the
expression array. Analyses were restricted to CpG sites with at
least a 5% difference of methylation between the phenotypicl Metabolism 18, 296–302, August 6, 2013 ª2013 Elsevier Inc. 297
Figure 1. Global Analysis of Methylation in Phenotypic Groups and after Bariatric Surgery
(A and B) Global analysis of the methylation patterns of the phenotypic groups (normal controls, healthy obese, steatosis and NASH). (A) shows a heatmap of the
74 CpGs resulting from an ANOVA analysis using an FDR <0.004. If the CpG is assigned to a gene locus, the respective gene name is provided in brackets. For
visualization, the means and variances are normalized to 0 and 1, respectively, for each gene. (B) shows the first three principal components analysis (PCA) of the
corresponding PCA.
(C and D) Analysis of the alteration in methylation patterns before and after bariatric surgery. (C) shows a heatmap of the 49 CpGs resulting from an ANOVA
analysis using an FDR < 0.01. If the CpG is assigned to a gene locus, the respective gene name is provided in brackets. (D) shows the first three PCA of the
corresponding PCA. See also Figure S1.
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DNA Methylation in NASH and Liver Remodelingextremes of normal controls and NASH and a minimum log2
change in mRNA expression of the respective gene/mRNA
of 0.2. According to these criteria, nine of the differentially
methylated genes also showed differential expression (p < 0.05
corrected for multiple testing, Online Supplement, http://
gengastro.1med.uni-kiel.de/suppl/methyl_liver/). With the ex-
ception of GRID1, expression and methylation at these loci
were closely inversely correlated, suggesting a causal role of
DNA methylation for differential expression of these genes in
the liver phenotypes (Figure S1A). Differential methylation for
the nine putative driver genes was technically validated in
42 samples and replicated in 39 independent samples (C/H/S/
N, 10/9/10/10) at a nominal significance level of p < 0.05 using
bisulfite pyrosequencing as an independent technology (Fig-
ure S2, Table 2).
Postbariatric Changes in CpG Methylation
The potential reversibility of DNA methylation changes associ-
ated with the progression from normal controls to NASH was298 Cell Metabolism 18, 296–302, August 6, 2013 ª2013 Elsevier Incevaluated. This was possible, because the postbariatric samples
were not used to determine the liver phenotype associated DNA
methylation patterns. A significant—though weak—inverse cor-
relation (Spearman rank test, p = 0.004, 9= –0.13) of DNAmethyl-
ation changes between NASH and normal controls on the one
hand and after (B2, i.e., ‘‘healthier,’’ improved histology) and
before (B1) bariatric surgery on the other hand was seen for the
467 CpG sites identified in the liver phenotype analysis. This
effect seen more clearly in the analysis of loci identified in the
pairwise comparison of CpG methylation between normal con-
trols and NASH at the q = 0.05 level by OMICs explorer (list of
CpGsnot shown) yielding apvalue of 1.63107 (9=–0.23).How-
ever, as reflected by the correlation coefficients of –0.13 and
–0.23, disease-associated methylation was only partially revers-
ible and restricted to a subset of loci. In a single CpG-based test
of differential methylation corrected for multiple testing, pheno-
type-associated methylation at the HOXB1, PRKCZ,
SLC38A10, and SECTM1 loci was reversible (Online Supple-
ment, http://gengastro.1med.uni-kiel.de/suppl/methyl_liver/)..
Table 2. Candidate Epigenetic Disease Driver Genes
Gene CpG Site pGROUP PNC PREPLIC DEXPR_NC DMeth_NC Gene Name putative function
GALNTL4 cg16337763 1.5 3 106 1.5 3 1005 0.0017 0.70 0.10 Putative polypeptide
N-acetylgalactosaminyl-
transferase-like protein 4
May catalize the initial reaction
in O-linked oligosaccharide
biosynthesis
ACLY cg25687894 6.1 3 105 5.4 3 1003 0.0036 0.38 0.09 ATP citrate lyase Primary enzyme for synthesis of
cytosolic acetyl-CoA
GRID1 cg27317356 8.5 3 105 1.1 3 1004 0.0026 1.35 0.13 Glutamate receptor
delta-1
Synaptic activity, expressed
in liver, function in relation to liver
metabolism poorly studied
IGFBP2 cg11669516 3.6 3 104 2.4 3 1004 0.015 1.43 0.20 Insulin-like growth factor
binding protein 2
Leptin-regulated; overexpression
reversed diabetes in murine models
PLCG1 cg18347630 2.5 3 104 3.6 3 1003 0.0031 0.33 0.05 Phospholipase
C-gamma-1
Production of diacylglycerol and
inositol 1,4,5-trisphosphate (IP3)
PRKCE cg04035064 2.8 3 104 2.7 3 1003 0.0035 0.85 0.12 Protein kinase C, epsilon Phospholipid- and diacylglycerol-
dependent serine/threonine-protein
kinase with broad regulatory
functions
IGF1 cg08806558 1.8 3 103 2.8 3 1004 0.013 0.93 0.13 Insulin-like growth
factor 1
Hormone similar in structure to
insulin, promotes growth, regulates
glucose uptake, glycogen synthesis,
cell proliferation





PC cg04174538 4.0 3 103 3.4 3 1004 0.0027 0.48 0.07 Pyruvate carboxylase initial reaction of glucose and lipid
synthesis from pyruvate
Genes with CpG sites differentially methylated between phenotypic groups with concomitant significant mRNA expression differences (normalized
log2 values). The data are a subset filtered from the online supplement according to the criteria provided in the Results. PGROUP denotes the p value
of the global phenotype association, PNC the pairwise comparison of the N and C group, and PREPLIC the independent replication p value in the methyl-
ation analysis. DEXPR_NC refers to the log2 expression difference between the N and C groups and DMeth_NC to the respective absolute difference in
methylation. Positive values in these two columns refer to higher values in the C group as compared to N (as calculated by Nminus C). See also Figures
S1 and S2.
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DNA Methylation in NASH and Liver RemodelingIn a paired analysis of CpG methylation before and after
bariatric surgery, a clear separation in the principal components
analyses according to the bariatric surgery status was seen
(Figure 1C). A total of 113 differentially methylated sites were
identified (q = 0.05). For these sites, a strong correlation of
differential methylation between the liver phenotypes (C versus
N) and bariatric surgery was observed (p < 2.2 3 1016, 9 =
–0.94); i.e., those CpGs losing methylation after bariatric surgery
typically gained methylation during progression from normal
liver to NASH and vice versa. Only four CpGs (two unannotated
and two in the HOXB1 locus) overlapped with the sites identified
in the phenotype group analyses at the same false discovery
rate (q = 0.05). Of the 113 CpGs from the bariatric analysis,
80 mapped to 32 gene loci, of which the gene encoding
protein-tyrosine phosphatase epsilon (PTPE) showed both dif-
ferential expression before and after bariatric surgery (last panel,
Figure 2).
Gene Ontology Analysis
The ten highest ranking gene ontology (GO) analysis terms
from the liver phenotype and bariatric analyses were compared.
Only four of the top ten terms were identical and included
generic biological processes. Interestingly, the six GO terms
specific for the bariatric analysis revealed terms sharing remod-Celeling and anatomical structure development as a common
theme and included ‘‘anatomical structure development’’ and
‘‘anatomical structure morphogenesis’’ (Table S2B).
Enrichment of Transcription Factor Binding Sites
We investigated whether the CpG sites differentially methylated
between liver phenotypes or after bariatric surgery were en-
riched for binding sites of any of the 73 TFs annotated in the liver
cell line HepG2 cells in the recently published ENCODE data set
(Dunham et al., 2012; Gerstein et al., 2012; Neph et al., 2012).
Highly significant enrichment of TF binding sites in both the
phenotype and bariatric remodeling groups was seen for TFs
ZNF274 (zinc finger protein 274, >7,000-fold enrichment in
both groups, maximum p value p < 1.0 3 10300, Fisher’s
exact test), PGC1A (peroxisome proliferator-activated receptor
gamma, coactivator 1 alpha, >2,000-fold, p < 1.0 3 10300),
SREBP2 (sterol regulatory element binding TF 2, >1,000-fold,
p < 3.8 3 10272), and GRP20 (glycine-rich protein 20,
>400-fold, p < 3.8 3 10233), implicating an involvement of
these factors in both disease and remodeling. While only
eight TFs, namely ZNF274, PGC1A, SREBF2, GRP20, ZEB1,
FOXA1, FOXA2, and RXA, were enriched in the phenotype
group using a cutoff of p < 0.007 (p < 0.05 corrected for 73 tests),
binding sites from 38 TFs were significantly enriched in thel Metabolism 18, 296–302, August 6, 2013 ª2013 Elsevier Inc. 299
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Figure 2. Methylation and Expression Data of Candidate Epigenetic Disease Driver Genes
Detailed depiction of the nine loci from the phenotype group analysis which showed both significant differences in methylation and mRNA expression in the liver
phenotype analysis. For each gene, the methylation data are given on the left side and the expression data on the right side. Groups are denoted as C (normal
controls), H (healthy obese), S (steatosis), N (NASH), B1 (before bariatric surgery), and B2 (after bariatric surgery). The tenth panel (bottom right) displays PTPE,
the one gene with significant changes both in the bariatric expression and methylation analysis. Error bars represent the interquartile ranges as calculated by
boxplot.stats() in R. See also Figure S2.
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DNA Methylation in NASH and Liver Remodelingbariatric CpG methylation signature, pointing to a broad repro-
gramming of the liver cells during this process. TFs with the high-
est relative enrichment in the bariatric as compared to the liver
phenotype analysis included NRF1 (nuclear respiratory factor
1, 466-fold), HSF1 (heat shock TF 1, 463-fold), ESRRA (estro-
gen-related receptor alpha, 454-fold), SRF (serum response
factor, 232-fold), TR4 (testicular receptor 4, 232-fold), CEBPZ
(CCAAT/enhancer binding protein zeta, 231-fold), and SREBP1
(sterol regulatory element binding TF, 153-fold). A full list for
all TF binding sites including mRNA expression analysis in
both the phenotypic and bariatric comparisons is provided
in Table S2.
DISCUSSION
Methylation as a Molecular Clock in the Model of
Disease Progression
CpG methylation may be used a ‘‘molecular clock’’ during the
development of the liver phenotype, which is thought to progress
from normal liver histology (i.e., ‘‘healthy obese’’ individuals
[Blu¨her, 2010; Kusminski et al., 2012; Tran et al., 2008]) through
simple steatosis to steatotic necroinflammation. Indeed, differ-
entially methylated CpG sites in the liver phenotype analysis
with either progressively increasing or decreasing methylation
across this phenotypic axis were highly overrepresented.300 Cell Metabolism 18, 296–302, August 6, 2013 ª2013 Elsevier IncCandidate Epigenetic Regulators of Disease
Nine genes showing both differential methylation and mRNA
expression were identified. The absolute differences in CpG
methylation between groups typically ranged between 5% and
15% and may reflect subpopulations of hepatocytes. Although
only a fraction of those has been studied in detail in relation to
NAFLD, their known functions are compatible with a putative
role as key drivers of the liver phenotype. They include key en-
zymes catalyzing the initial steps in glucose, lipid, acetyl-CoA,
and oligosaccacharide synthesis and pathway members of
insulin-like signaling mediators. A true mechanistic understand-
ing and experimental proof of this disease driver claim will
require further experiments. For two (ACLY, IGFBP2) of the
nine putative driver genes, high-quality mechanistic studies in
NASH models are available: ACLY (ATP citrate lyase) catalyzes
conversion of citrate into acetyl-CoA, the building block for the
endogenous biosynthesis of fatty acids (Chypre et al., 2012),
putting this enzyme at a crosslink between glucose metabolism
and fatty acid synthesis. Its mRNA is regulated by SREBP-1, one
of the TFs implicated in the bariatric remodeling response in this
study (Bauer et al., 2005). Abrogation of hepatic ACLY, which is
upregulated in our human mRNA data set, protects against
steatosis in leptin-receptor-deficient mice (Wang et al., 2009).
The IGFBP2 (insulin-like growth factor binding protein 2) locus
was hypermethylated and its mRNA downregulated in NASH..
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DNA Methylation in NASH and Liver RemodelingThis observation is consistent with animal data, as adenoviral
overexpression of IGFBP2 has been shown to reverse diabetes
and steatosis in obese mice (Hedbacker et al., 2010).
A key role for IGF1 (insulin-like growth factor 1), a hormone
responsible for many of the systemic effects of growth hormone
(GH), for liver metabolism is increasingly being recognized
(Takahashi, 2012). Low serum IGF1 (consistent with the liver
data obtained in this study) has been identified as a marker of
liver steatosis and NASH (Garcı´a-Galiano et al., 2007). Mice
with a liver-specific deletion of the growth hormone receptor,
which show a >90% reduction of IGF-1, exhibited severe hepatic
steatosis (Fan et al., 2009).
This study did not include patients with advanced NASH and
high fibrosis grades.While this provides a relatively homogenous
phenotype spectrum and ensures a more homogenous cell
population between phenotype groups, it limits the applicability
of our findings. Indeed, fibrosis progression will likely have a
distinct epigenetic signature that is not reflected in our results.
Remodeling Signature after Weight Loss
Both GO and TF binding site analysis revealed striking differ-
ences between the liver phenotype and bariatric comparisons.
An inverse correlation of NASH phenotype and bariatric
remodeling was observed, indicating that NASH-associated
methylation changes can indeed be reversed. The gene encod-
ing protein-tyrosine phosphatase epsilon (PTPRE) showed both
a differential expression and differential methylation before and
after bariatric surgery. Hypermethylation and transcriptional
downregulation of PTPRE—which is a negative regulator of insu-
lin signaling in skeletal muscle (Aga-Mizrachi et al., 2008)—after
bariatric surgery may thus represent a key mechanism in the
restitution of hepatic insulin sensitivity during weight loss.
While the presented study is limited in terms of sample size,
phenotype coverage, and technology, it represents a genome-
wide assessment of CpG methylation in NAFLD and its dynamic
change induced by the weight loss after bariatric surgery in
humans. Some of the candidate epigenetic driver genes may
represent attractive targets for future mechanistic studies and
therapeutic interventions. Likewise, the epigenetic remodeling
signature after bariatric surgery provides a data set of epigenetic




Liver samples were obtained percutaneously for patients undergoing liver
biopsy for suspected NAFLD or intraoperatively for assessment of liver
histology. Normal control samples were recruited from samples obtained for
exclusion of liver malignancy during major oncological surgery. None of the
normal control individuals underwent preoperative chemotherapy, and liver
histology demonstrated absence of both cirrhosis and malignancy. Consent-
ing patients underwent a routine liver biopsy during bariatric surgery for
assessment of liver affection. Biopsies were immediately frozen in liquid nitro-
gen, ensuring an ex vivo time of less than 40 s in all cases. A percutaneous
follow-up biopsy was obtained in consenting bariatric patients 5–9 months
after surgery. Patients with evidence of viral hepatitis, hemochromatosis, or
alcohol consumption greater than 20 g/day for women and 30 g/day for men
were excluded. All patients provided written, informed consent. The study
protocol was approved by the institutional review board (‘‘Ethikkommission
der Medizinischen Fakulta¨t der Universita¨t Kiel,’’ D425/07, A111/99) beforeCelthe commencement of the study. Standardized histopathological assessment
(Kleiner et al., 2005) was performed by a single pathologist blinded to the
molecular analyses. Of the 23 postbariatric patients, 20 underwent a sleeve
gastrectomy and 3 a gastric bypass procedure.
DNA Methylation and Expression Analysis
For homogenization of 5–10 mg frozen tissue and subsequent nucleic acid
isolation, tubes with 1,4 mm ceramic beads (Precellys, Villeurbanne, France)
and the AllPrep DNA/RNA Mini Kit (QIAGEN, Hilden, Germany) were used.
Bisulfite conversion used the Zymo EZ DNA Methylation Kit (Zymo
Research, Orange, CA, USA). Hybridization of the HumanMethylation450k
Bead Chip (Illumina, SanDiego, CA), subsequent scanning (iScan, Illumina),
and mRNA expression analysis using the HuGene 1.1 ST gene (Affymetrix,
Santa Clara, Ca, USA) were performed according to the manufacturers
protocols. DNA and RNA chip data are available in GEO (GSE48325,
GSE48452).
Statistics and Data Analysis
Hybridization signals were analyzed using GenomeStudio software (default
settings; GenomeStudio version 2011.1, Methylation Analysis Module
version 1.9.0; Illumina Inc) and internal controls for normalization. Identifi-
cation of differentially methylated loci and generation of the heat maps or
pairwise group comparisons analysis followed by cluster analyses, and
PCA was performed using the OMICS explorer (version 2.3, Qlucore, Lund,
Sweden). If not otherwise stated, clustering was based on correlation
(mean = 0, variance = 1). The weighted average was used to generate the
heatmaps.
All other analyses were performed in R (R Development Core Team, 2010).
Pairwise comparisons of methylation or mRNA expression differences were
performed using the Wilcoxon test.
Gene Ontology Analysis
GO analyses for biological process were performed using topGO package
(Alexa et al., 2006) in R. The minimal nominal uncorrected p value of each
gene from the Wilcoxson test in the pairwise group comparisons was used
as a weight vector in the ‘‘classic’’ Komolgorov-Smirnov test as implemented
in the topGO package. GO analyses was restricted to terms with a node size of
R10. Only CpG sites that were annotated to a gene locus (Illumina) were
utilized.
Analysis of Transcription Factor Binding Enrichment
For enrichment analysis of CpG islands in liver-specific open chromatin struc-
tures, the called peaks of signal enrichment based on pooled, normalized
(interpreted) data for the HepG2 cell line were downloaded on 10/16/2012
from the ENCODE Open Chromatin by DNaseI HS Track (http://genome.
ucsc.edu/cgi-bin/hgTrackUi?g=wgEncodeDNAseSuper). The called peaks
for signal enrichment of TF binding sites in the HepG2 cell line were down-
loaded from the ENCODE Transcription Factor Binding Track on September
15, 2012. CpGs that mapped within or ±1 bp of an annotated TF binding site
were considered positive for the respective TF.SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online.
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